Abstract
Summary
The global Long-Acting Injectable (LAI) Antipsychotic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Long-Acting Injectable (LAI) Antipsychotic players cover Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada and Prolixin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.
LPI (LP Information)' newest research report, the “Long-Acting Injectable (LAI) Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-Acting Injectable (LAI) Antipsychotic sales in 2022, providing a comprehensive analysis by region and market sector of projected Long-Acting Injectable (LAI) Antipsychotic sales for 2023 through 2029. With Long-Acting Injectable (LAI) Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting Injectable (LAI) Antipsychotic industry.
This Insight Report provides a comprehensive analysis of the global Long-Acting Injectable (LAI) Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-Acting Injectable (LAI) Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting Injectable (LAI) Antipsychotic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting Injectable (LAI) Antipsychotic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting Injectable (LAI) Antipsychotic.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting Injectable (LAI) Antipsychotic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Aripiprazole
Fluphenazine
Haloperidol
Others
Segmentation by application
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin
United States market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Long-Acting Injectable (LAI) Antipsychotic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Long-Acting Injectable (LAI) Antipsychotic players cover Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada and Prolixin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.
LPI (LP Information)' newest research report, the “Long-Acting Injectable (LAI) Antipsychotic Industry Forecast” looks at past sales and reviews total world Long-Acting Injectable (LAI) Antipsychotic sales in 2022, providing a comprehensive analysis by region and market sector of projected Long-Acting Injectable (LAI) Antipsychotic sales for 2023 through 2029. With Long-Acting Injectable (LAI) Antipsychotic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-Acting Injectable (LAI) Antipsychotic industry.
This Insight Report provides a comprehensive analysis of the global Long-Acting Injectable (LAI) Antipsychotic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-Acting Injectable (LAI) Antipsychotic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-Acting Injectable (LAI) Antipsychotic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-Acting Injectable (LAI) Antipsychotic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-Acting Injectable (LAI) Antipsychotic.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-Acting Injectable (LAI) Antipsychotic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Aripiprazole
Fluphenazine
Haloperidol
Others
Segmentation by application
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alkermes
Eli Lilly and Company
Janssen Global Services, LLC
Abilify Maintena
Haldol
Otsuka Pharmaceutical
Aristada
Prolixin
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Long-Acting Injectable (LAI) Antipsychotic Market Size 2018-2029
2.1.2 Long-Acting Injectable (LAI) Antipsychotic Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Long-Acting Injectable (LAI) Antipsychotic Segment by Type
2.2.1 Aripiprazole
2.2.2 Fluphenazine
2.2.3 Haloperidol
2.2.4 Others
2.3 Long-Acting Injectable (LAI) Antipsychotic Market Size by Type
2.3.1 Long-Acting Injectable (LAI) Antipsychotic Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Type (2018-2023)
2.4 Long-Acting Injectable (LAI) Antipsychotic Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Others
2.5 Long-Acting Injectable (LAI) Antipsychotic Market Size by Application
2.5.1 Long-Acting Injectable (LAI) Antipsychotic Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Application (2018-2023)
3 Long-Acting Injectable (LAI) Antipsychotic Market Size by Player
3.1 Long-Acting Injectable (LAI) Antipsychotic Market Size Market Share by Players
3.1.1 Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Players (2018-2023)
3.1.2 Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Players (2018-2023)
3.2 Global Long-Acting Injectable (LAI) Antipsychotic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Long-Acting Injectable (LAI) Antipsychotic by Regions
4.1 Long-Acting Injectable (LAI) Antipsychotic Market Size by Regions (2018-2023)
4.2 Americas Long-Acting Injectable (LAI) Antipsychotic Market Size Growth (2018-2023)
4.3 APAC Long-Acting Injectable (LAI) Antipsychotic Market Size Growth (2018-2023)
4.4 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size Growth (2018-2023)
4.5 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size Growth (2018-2023)
5 Americas
5.1 Americas Long-Acting Injectable (LAI) Antipsychotic Market Size by Country (2018-2023)
5.2 Americas Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023)
5.3 Americas Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting Injectable (LAI) Antipsychotic Market Size by Region (2018-2023)
6.2 APAC Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023)
6.3 APAC Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Long-Acting Injectable (LAI) Antipsychotic by Country (2018-2023)
7.2 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023)
7.3 Europe Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic by Region (2018-2023)
8.2 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Type (2018-2023)
8.3 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.1 Global Long-Acting Injectable (LAI) Antipsychotic Forecast by Regions (2024-2029)
10.1.1 Global Long-Acting Injectable (LAI) Antipsychotic Forecast by Regions (2024-2029)
10.1.2 Americas Long-Acting Injectable (LAI) Antipsychotic Forecast
10.1.3 APAC Long-Acting Injectable (LAI) Antipsychotic Forecast
10.1.4 Europe Long-Acting Injectable (LAI) Antipsychotic Forecast
10.1.5 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Forecast
10.2 Americas Long-Acting Injectable (LAI) Antipsychotic Forecast by Country (2024-2029)
10.2.1 United States Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.2.2 Canada Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.2.3 Mexico Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.2.4 Brazil Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.3 APAC Long-Acting Injectable (LAI) Antipsychotic Forecast by Region (2024-2029)
10.3.1 China Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.3.2 Japan Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.3.3 Korea Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.3.4 Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.3.5 India Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.3.6 Australia Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.4 Europe Long-Acting Injectable (LAI) Antipsychotic Forecast by Country (2024-2029)
10.4.1 Germany Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.4.2 France Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.4.3 UK Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.4.4 Italy Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.4.5 Russia Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.5 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Forecast by Region (2024-2029)
10.5.1 Egypt Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.5.2 South Africa Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.5.3 Israel Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.5.4 Turkey Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.5.5 GCC Countries Long-Acting Injectable (LAI) Antipsychotic Market Forecast
10.6 Global Long-Acting Injectable (LAI) Antipsychotic Forecast by Type (2024-2029)
10.7 Global Long-Acting Injectable (LAI) Antipsychotic Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Alkermes
11.1.1 Alkermes Company Information
11.1.2 Alkermes Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Alkermes Main Business Overview
11.1.5 Alkermes Latest Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Information
11.2.2 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Eli Lilly and Company Main Business Overview
11.2.5 Eli Lilly and Company Latest Developments
11.3 Janssen Global Services, LLC
11.3.1 Janssen Global Services, LLC Company Information
11.3.2 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Janssen Global Services, LLC Main Business Overview
11.3.5 Janssen Global Services, LLC Latest Developments
11.4 Abilify Maintena
11.4.1 Abilify Maintena Company Information
11.4.2 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Abilify Maintena Main Business Overview
11.4.5 Abilify Maintena Latest Developments
11.5 Haldol
11.5.1 Haldol Company Information
11.5.2 Haldol Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Haldol Main Business Overview
11.5.5 Haldol Latest Developments
11.6 Otsuka Pharmaceutical
11.6.1 Otsuka Pharmaceutical Company Information
11.6.2 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Otsuka Pharmaceutical Main Business Overview
11.6.5 Otsuka Pharmaceutical Latest Developments
11.7 Aristada
11.7.1 Aristada Company Information
11.7.2 Aristada Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Aristada Main Business Overview
11.7.5 Aristada Latest Developments
11.8 Prolixin
11.8.1 Prolixin Company Information
11.8.2 Prolixin Long-Acting Injectable (LAI) Antipsychotic Product Offered
11.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Prolixin Main Business Overview
11.8.5 Prolixin Latest Developments
12 Research Findings and Conclusion